Eprontia (Topiramate) Patent Expiration, LOE Window & CMS Spending

Eprontia (Topiramate) by Azurity: FDA Orange Book LOE 2040-08-21, 1 AB generics, $10.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN214679 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-08-21
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$10.1M
2024 Medicare Part D Spend$896K
2024 Medicaid Spend$9.2M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 23.5% 2-yr change)